Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,150 public posts
Filter results
Dream Cruise
I've never been told
castration
resistant but I assume so. His pathology report showed 12 of 12 cores 5+4. We all know what that means. Why the heck would they NOT approve Zytiga? Any words of wisdom would be appreciated! Love you all! Barb PS...
I've never been told
castration
resistant but I assume so. His pathology report showed 12 of 12 cores 5+4. We all know what that means. Why the heck would they NOT approve Zytiga? Any words of wisdom would be appreciated! Love you all! Barb PS...
Brbnbrn
in
Advanced Prostate Cancer
5 years ago
Prostate Cancer Germline Genetics in Clinical Practice
However, there is strong evidence that patients with metastatic,
castration
resistant prostate cancer who have DNA damage repair defects respond positively to targeting PARP enzymes.
However, there is strong evidence that patients with metastatic,
castration
resistant prostate cancer who have DNA damage repair defects respond positively to targeting PARP enzymes.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Oral docetaxel
They completed a Phase I trial with prostate cancer patients and apparently did well enough that they say that they've started a Phase II with breast cancer patients and are planning a Phase IIb clinical trial for metastatic
castration
resistant prostate cancer - for which they say they have FDA approval
They completed a Phase I trial with prostate cancer patients and apparently did well enough that they say that they've started a Phase II with breast cancer patients and are planning a Phase IIb clinical trial for metastatic
castration
resistant prostate cancer - for which they say they have FDA approval
AlanMeyer
in
Advanced Prostate Cancer
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Cabazitaxel Plus Carboplatin for the Treatment of Men With Metastatic Castration-Resistant Prostate Cancer
"TAKE-HOME MESSAGE This phase I/II trial evaluated the combination of cabazitaxel and carboplatin for patients with metastatic
castration
-resistant prostate cancer.
"TAKE-HOME MESSAGE This phase I/II trial evaluated the combination of cabazitaxel and carboplatin for patients with metastatic
castration
-resistant prostate cancer.
snoraste
in
Advanced Prostate Cancer
5 years ago
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
"The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic
castration
-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative
"The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic
castration
-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive PCa.
"
Castration
therapy" would perhaps be clearer. The term CRPC (castrate-resistant PCa) is clear enough, but what is the term for failing Abi monotherapy or Abi+classic ADT?
"
Castration
therapy" would perhaps be clearer. The term CRPC (castrate-resistant PCa) is clear enough, but what is the term for failing Abi monotherapy or Abi+classic ADT?
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Need Advice-Bipolar Androgen Therapy
He has
castration
-resistant prostate cancer with progression despite abiraterone, enzalutamide, and docetaxel chemotherapy and radium-223. His alkaline phosphate were about 1500 prior to the start and now they are almost normal. However his PSA remains around 500.
He has
castration
-resistant prostate cancer with progression despite abiraterone, enzalutamide, and docetaxel chemotherapy and radium-223. His alkaline phosphate were about 1500 prior to the start and now they are almost normal. However his PSA remains around 500.
Amandaslp78
in
Advanced Prostate Cancer
5 years ago
CRPC & 'Drug Repositioning'
Screening of Drug Repositioning Candidates for
Castration
Resistant Prostate Cancer. Kim IW1, Kim JH1, Oh JM1. Author information 1 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul, South Korea.
Screening of Drug Repositioning Candidates for
Castration
Resistant Prostate Cancer. Kim IW1, Kim JH1, Oh JM1. Author information 1 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul, South Korea.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Radium-223 in Clinical Practice. Video
"In conclusion, the ERA-223 study highlights the importance of bone health, a topic in need of quality improvement, as it represents an area of high-value care for men with
castration
-resistant prostate cancer.
"In conclusion, the ERA-223 study highlights the importance of bone health, a topic in need of quality improvement, as it represents an area of high-value care for men with
castration
-resistant prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
New prostate cancer treatment concept
Recent clinical trials have hinted that combining immunotherapy and radiation therapy may be a powerful treatment approach for
castration
-resistant prostate cancer. https://medicalxpress.com/news/2019-08-prostate-cancer-treatment-concept.html
Recent clinical trials have hinted that combining immunotherapy and radiation therapy may be a powerful treatment approach for
castration
-resistant prostate cancer. https://medicalxpress.com/news/2019-08-prostate-cancer-treatment-concept.html
George71
in
Advanced Prostate Cancer
5 years ago
PSMA Heterogeneity and DNA Repair Defects in Prostate Cancer
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
Balsam01
in
Advanced Prostate Cancer
5 years ago
Docetaxel Improves Survival in Metastatic Hormone-Naïve Prostate Cancer
The ENZAMET trial had a
castration
-sensitive metastatic population. Enzalutamide had previously been FDA approved for metastatic castrate-resistant docetaxel, metastatic castrate resistance first line, and nonmetastatic castrate resistance.
The ENZAMET trial had a
castration
-sensitive metastatic population. Enzalutamide had previously been FDA approved for metastatic castrate-resistant docetaxel, metastatic castrate resistance first line, and nonmetastatic castrate resistance.
Balsam01
in
Advanced Prostate Cancer
5 years ago
PSMA Heterogeneity and DNA Repair Defects in Prostate Cancer
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
snoraste
in
Advanced Prostate Cancer
5 years ago
PSMA Heterogeneity and DNA Repair Defects in Prostate Cancer
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
Balsam01
in
Advanced Prostate Cancer
5 years ago
PSMA Heterogeneity and DNA Repair Defects in Prostate Cancer
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
The expression of membranous PSMA was heterogeneous, more common in
castration
-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006).
snoraste
in
Advanced Prostate Cancer
5 years ago
Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show
Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show Sep 04, 2019 01:03 pm | Jose Marques Lopes, PhD Onvansertib Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic
castration
-resistant
Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show Sep 04, 2019 01:03 pm | Jose Marques Lopes, PhD Onvansertib Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic
castration
-resistant
JLS1
in
Advanced Prostate Cancer
5 years ago
Abiraterone added to Lupron
I am not
castration
resisdent at this point and responded well to it for the full year I was on Lupron. Question - he also he might also suggest Abriraterone to the lupron as an added benefit to me. Is Abiraterone ( Zytiga ) a pill?
I am not
castration
resisdent at this point and responded well to it for the full year I was on Lupron. Question - he also he might also suggest Abriraterone to the lupron as an added benefit to me. Is Abiraterone ( Zytiga ) a pill?
ken12491
in
Advanced Prostate Cancer
5 years ago
Darolutamide & Rosuvastatin
Abstract BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic
castration
-resistant prostate cancer (nmCRPC).
Abstract BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic
castration
-resistant prostate cancer (nmCRPC).
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Enzalutamide [Xtandi] & altered sense of Taste
Case 1: A 72-year-old man developed
castration
-resistant prostate cancer (CRPC) and was administered enzalutamide.
Case 1: A 72-year-old man developed
castration
-resistant prostate cancer (CRPC) and was administered enzalutamide.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
$200 honorarium - Online Patient and caregiver research for stage 4 prostate cancer OR non-metastatic castration-resistant prostate cancer
Online Patient and caregiver research for stage 4 prostate cancer OR non-metastatic
castration
-resistant prostate cancer Find A Cure Panel has some new online patient research for patients and caregivers of people with metastatic/stage 4 prostate cancer or non-metastatic
castration
-resistant prostate
Online Patient and caregiver research for stage 4 prostate cancer OR non-metastatic
castration
-resistant prostate cancer Find A Cure Panel has some new online patient research for patients and caregivers of people with metastatic/stage 4 prostate cancer or non-metastatic
castration
-resistant prostate
Darryl
Partner
in
Prostate Cancer Caregivers
5 years ago
1
...
37
38
39
...
58
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1024 results
Fight Prostate Cancer
70 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest